Objective-The regeneration of the hematopoietic system in bone marrow after chemotherapy depends on a balance between the quiescence and proliferation of lineage-specific progenitor cells. Even though the vascular network in bone is damaged by cytoablation, the transcriptional control of quiescence in endothelial cells is not well known. In this study, we investigated the role of the transcription factor E74-like factor (ELF4) in the proliferation of endothelial cells in bone marrow. Methods and Results-Loss-of-function models were used to study the role of ELF4 in human and murine endothelial cells. ELF4 promotes cell cycle entry by activating cyclin-dependent kinase-4 in human umbilical vein endothelial cells. 
C ellular quiescence protects tissue-specific progenitor cells from cell cycle-dependent cytotoxicity to ensure longevity and regenerative potential. This reversible cell cycle arrest is actively regulated by cell-intrinsic factors, in addition to proliferation-inducing signals from the milieu. 1 Chemotherapeutic drugs that target dividing cells cause ablation of hematopoietic and endothelial cells in the bone marrow (BM). 2, 3 The molecular events that protect endothelial cells from apoptosis and disruption of cell-cell junctions following administration of cytotoxic drugs that ultimately lead to the regression of sinusoidal blood vessels (SBVs) in BM are not well understood. 4 E74-like factor (ELF4) is a member of the E-twenty six (ETS) family of transcription factors defined by a highly conserved DNA-binding domain (ETS domain). 5, 6 ELF4 has a tumor suppressor function in acute myelogenous leukemias by gene repression or chromosomal translocation with the ERG gene. [7] [8] [9] [10] However, ELF4 can also have oncogenic properties in ovarian cancer. 11 In the hematopoietic system, ELF4 activates the cytotoxicity of natural killer cells and negatively regulates quiescence in hematopoietic stem cells (HSCs). 12, 13 We recently reported that ELF4 also inhibits T-cell proliferation downstream of T cell receptor (TCR) and mammalian target of rapamycin (mTOR) signaling by activating the tumor suppressor KLF4. 14, 15 In this work, we addressed whether ELF4 controls proliferation in a nonhematopoietic cell lineage.
ETS proteins are important transcriptional regulators for the development and function of endothelial cells. 16 Furthermore, the enhancers and promoters of many endothelialspecific genes are regulated by ETS proteins. 16 For instance, ETS1, ERG, Fli-1, ELF1, and TEL are involved in vascular development and angiogenesis. 17 ELF4 is highly homologous to ELF1, ELF2 (also known as NERF2), ELF3, and ELF5, 6 a subfamily involved in the regulation of Tie2 gene expression. 18, 19 Similarly to ETS1, deletion of the Elf4 gene is not embryonic lethal, suggesting either functional redundancy or function in adult tissues. Despite the lack of developmental defects observed in loss-of-function mouse models generated by homozygous gene deletion, these models can still provide information about unique functions in processes of vascular remodeling in adult tissues not compensated by homologous ETS proteins. 20 -24 The vasculature in BM is a complex network that includes SBVs that traverse the bone cavity from the endosteum to the central sinus. In contrast to other blood vessels, SBVs are formed by a discontinuous single layer of endothelial cells to allow maximal permeability. 25 Thus, hematopoietic cells and metastatic tumor cells (ie, breast and prostate cancer) can exit or home in BM via SBVs. An additional function of BM endothelial cells is to provide HSCs with a microenvironment that signals proliferation, differentiation, and mobilization. 2, 26, 27 Chemically induced cytoablation leads to a collapse and regression of SBVs because of a reduction of the BM cellularity that normally supports the vascular network in BM. 2, 3, 28 The regulation of quiescence in endothelial cells during homeostasis has not been previously addressed. We postulated that quiescent endothelial cells in BM would be spared from chemical ablation, as happens with HSCs, resulting in heightened regeneration of blood vessels in BM.
In this work, we report that ELF4 promoted cell cycle entry in human umbilical vein endothelial cells (HUVECs). Thus, silencing of ELF4 gene expression led to increased quiescence in HUVECs because of the downregulation of cyclindependent kinase (cdk)-4 expression. In agreement with this finding, Elf4 Ϫ/Ϫ mice revealed enhanced recovery of BM CD45 Ϫ CD31 ϩ endothelial cells and regeneration of SBV after cytoablation due to a lower proliferation rate at steady state. These data support the hypothesis that ELF4 negatively regulates quiescence in endothelial cells similarly to HSCs. 13 
Methods

Cells
HUVECs were obtained from Lonza and cultured following the manufacturer's instructions. NIH3T3 and COS-7 cells were obtained from American Type Culture Collection.
Mice
Elf4
Ϫ/Ϫ mice were obtained from S. Nimer and described previously. 12 C57BL/6 mice were purchased from the Jackson Laboratory. For cytoablation, a single dose of 5-fluorouracil (5-FU) was administered intraperitoneally (150 mg/kg). All mice were bred and maintained in specific pathogen-free conditions at the Baylor College of Medicine. All experiments were approved by the Institutional Animal Care and Usage Committee of Baylor College of Medicine.
Promoter Assays
ELF4 cDNA was cloned into the cytomegalovirus 5 (CMV5) expression vector. cMYC cDNA was obtained from Addgene and then cloned into the CMV5 plasmid. The human CDK4 promoter obtained from Addgene was cloned into the pGL3-basic vector (Promega). COS-7 and NIH3T3 cells were transfected with a mixture of plasmids (CMV5-ELF4 or CMV5-cMYC), pGL3-CDK4, and Renilla luciferase plasmids using Lipofectamine 2000 (Invitrogen). Luciferase activity was measured using the dual-luciferase reporter assay system (Promega) and a luminometer (Sirius, Berthold).
Detection of ELF4 Expression
HUVECs were grown on slides and fixed with 1% paraformaldehyde in PBS for 10 minutes at room temperature. Cells were permeabilized with 0.1% Triton X-100 in PBS for 15 minutes and then incubated with 5% bovine serum albumin in PBS for 30 minutes. HUVECs were incubated with rabbit anti-human ELF4 (Orbigen) followed by anti-rabbit IgG conjugated with Alexa Fluor 488 (Invitrogen). Phalloidin-Alexa Fluor 555 (Invitrogen) was used to detect F-actin. Murine endothelial cells were purified from BM using anti-CD31 and BD-IMag (BD Biosciences) and spun onto glass slides. Following fixation and permeabilization as described above, cells were incubated with anti-CD45-fluorescein isothiocyanate or anti-CD31-fluorescein isothiocyanate, and anti-ELF4. 12 Slides were mounted with ProLong Gold antifade reagent (Invitrogen), and images were taken using a Nikon 90i microscope. ELF4 expression was also determined in paraffin fixed sections of mouse embryos (14.5 days post coitum) using an affinity-purified polyclonal antibody against ELF4 as previously described. 13 
Cell Cycle Analysis
DNA content was determined using propidium iodine as described previously 13 and analyzed using a FACScanto cytometer (BD Biosciences) and ModFit LT software (Verity). For the nuclear detection of Ki67, cells were fixed and permeabilized using reagents from the apo-5-bromo-2Ј-deoxyuridine kit (BD Biosciences) and stained with anti-Ki67-fluorescein isothiocyanate (Vector Laboratories) and 7-aminoactinomycin D. Murine endothelial cells were identified by flow cytometry using anti-CD31 and anti-CD45 antibodies. Samples were analyzed using FACScanto cytometer and FlowJo software (Tree Star).
Levels of cell cycle regulators in HUVECs treated with control short hairpin RNA (shRNA) or ELF4shRNA were evaluated by immunoblots using polyclonal anti-p21 (eBioscience) and rabbit polyclonal anti-p27, mouse anti-cyclin D1, mouse anti-cyclin D3, mouse anti-cdk4, and rabbit anti-phospho-Rb (Cell Signaling Technology). ELF4 was detected using rabbit polyclonal anti-ELF4. ␤-Actin was used to normalize sample loading.
Detection of Blood Vessels
Femurs were fixed and decalcified (Fisher Diagnostic) and embedded in paraffin. To identify bone vasculature, sections were stained with anti-MECA32 (Becton Dickinson). Morphometric analysis was performed to enumerate capillaries and SBV in different sections using NEI-Elements software (Nikon). Capillaries and SBV were identified based on morphology (hematoxylin and eosin staining) and MECA32 expression. 2, 3 Tissue sections were reviewed by a pathologist at Texas Children's Hospital. BM cells were cultured on fibronectin-coated plates for 14 days in F12K media (American Type Culture Collection) supplemented with 10% fetal bovine serum, 0.1 mg/mL heparin, and 0.03 mg/mL of endothelial cell growth supplement. Adherent cells were incubated with Alexa Fluor 488 Dil-Ac-LDL (5 g/mL) for 3 to 4 hours at room temperature, and positive colonies were counted under a fluorescence microscope. Percentage of Dil-Ac-LDL-positive endothelial cells was confirmed by flow cytometry using F4/80 antibody to rule out macrophages.
Immunofluorescence in Yolk Sac
Mouse embryos (9.5 days post coitum) were fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton X-100 in PBS for 10 minutes, and blocked with MOM solution (Vector Laboratories). Yolk sac was stained overnight with mouse anti-smooth-muscle actin (Dako), rat anti-CD31 (Becton Dickinson), and affinitypurified rabbit anti-ELF4 at 4°C. Tissues were then incubated with anti-mouse Alexa Fluor 488, anti-rat Alexa Fluor 633, and anti-rabbit Alexa Fluor 568 (Invitrogen). Images were taken using a Zeiss Axioplan 2 microscope.
Gene Silencing in HUVECs
HUVECs were transfected with 30 pmol of ELF4 Stealth RNAi or Stealth RNAi negative control (medium GC content) using Lipofectamine RNAiMax (Invitrogen) for 6 hours at 37°C. Cells were cultured for an additional 48 hours in EGM-2 medium. Expression of ELF4 was measured by real-time polymerase chain reaction using the following primers: 5Ј-TCCGAAATGCTTCCAGACTC-3Ј and 5Ј-GGGTCAGTGACAGGTGAGGT-3Ј. For ␤-actin, the following primers were used: 5Ј-CAAACATGATCTGGGTCATCTTCTC-3Ј and 5Ј-GCTCGTCGTCGACAACGGCTC-3Ј.
Results
Loss of ELF4 Leads to Enhanced Regeneration of SBV in BM
We previously described ELF4 as a negative regulator of quiescence in HSC during homeostasis but not during regen-erative hematopoiesis. 13 The increased hematologic recovery post-cytoablative treatment observed in Elf4 Ϫ/Ϫ mice was due to a larger pool of more quiescent HSCs. 13 Based on this finding, we tested whether ELF4 also controls neovascularization of BM by regulating quiescence of endothelial progenitor cells. We first confirmed that ELF4 is expressed in the nuclei of HUVECs, endothelium of blood vessels, and endocardium of 14.5 days post coitum mouse embryos ( Figure 1A and 1B). To correlate ELF4 expression with blood vessels, we performed whole-mount immunofluorescence of the yolk sac of embryos at 9.5 days post coitum using CD31 as marker of endothelial cells ( Figure 1C ). Finally, we purified CD31 ϩ murine BM cells and observed that ELF4 is expressed in both hematopoietic (CD45 positive) and nonhematopoietic (CD45 negative) cells ( Figure 1D ). ELF4 expression showed a nuclear punctuate pattern in CD45 Ϫ CD31 ϩ BM cells, which was reminiscent of the expression pattern in HSC, 13 suggesting that ELF4 is associated with a not well-defined nuclear domain. Collectively, these findings confirm that ELF4 is expressed in endothelial cells.
Both hematopoietic and vasculature systems are disrupted in the BM after administration of 5-FU. 3 Because ELF4 promotes cell cycle entry of HSCs at steady state, 13 we monitored the expansion of BM endothelial cells and regeneration of SBV in ablated Elf4-null mice. We enumerated CD45 Ϫ CD31 ϩ BM cells in femurs of 5-FU-treated mice by flow cytometry (Figure 2 ). Increased expansion of BM CD45 Ϫ CD31 ϩ endothelial cells was observed in Elf4 Ϫ/Ϫ mice between 9 and 12 days. Elf4 Ϫ/Ϫ femurs also exhibited increased numbers of endothelial cells 3 days after 5-FU administration, indicating that more endothelial cells survived this treatment compared with wild-type mice. We confirmed this acute effect by culturing BM cells on fibronectin-coated plates and incubating them with Dil-Ac-LDL to count colonies of endothelial cells representative of the initial number in BM isolate. Three days after 5-FU administration, the number of Dil-Ac-LDL-positive colonies recovered from BM was significantly higher in Elf4 Ϫ/Ϫ femurs compared with wildtype femurs ( Figure 3A) .
To investigate whether this increase in number of BM endothelial cells leads to heightened regeneration of SBVs, we examined the expression of MECA-32, a panendothelial marker, in femurs of wild-type and Elf4 Ϫ/Ϫ mice after 5-FU treatment (Supplemental Figure I , available online at http://atvb.ahajournals.org). Even though the number of capillaries in Elf4 Ϫ/Ϫ femurs was similar to that in wild-type femurs, the number of SBVs was significantly higher in Elf4 Ϫ/Ϫ femurs, correlating with a peak of expansion in CD45 Ϫ CD31 ϩ BM cells ( Figure 3B ). This finding suggested increased quiescence of cells at steady state or enhanced regenerative proliferation of Elf4 nϭ5), consistent with a higher number of Dil-Ac-LDLpositive colonies ( Figure 3A) . Therefore, a paucity of proliferation in Elf4 Ϫ/Ϫ BM endothelial cells could account for the improved regeneration of BM vasculature.
ELF4 Regulates Proliferation in BM Endothelial Cells
We previously reported that ELF4 promotes cell cycle entry in HSCs and induces cell cycle arrest in naïve CD8 ϩ T cells. 13, 14 These findings suggest that ELF4 activates the expression of genes involved in cell cycle regulation in a cell context-dependent manner. Therefore, we investigated whether ELF4 also controls the proliferation of BM endothelial cells during homeostasis. Analysis of DNA content revealed a lower percentage of Elf4 Ϫ/Ϫ CD45 Ϫ CD31 ϩ BM cells in S phase during homeostasis ( Figure 4A and 4B) . Next, a combination of Ki67 expression in nuclei and DNA content was used to distinguish cells in G 0 from those in G 1 .
Elf4
Ϫ/Ϫ CD45 Ϫ CD31 ϩ BM cells showed a significant increase in G 0 phase (Ki67 Ϫ/lo 2n DNA) of the cell cycle ( Figure 4C and 4D ). This finding suggests that a relatively low proliferative capacity of Elf4 Ϫ/Ϫ BM endothelial cells, defined as CD45 Ϫ CD31 ϩ , leads to accelerated survival and regeneration of SBVs, coinciding with the hematologic recovery previously reported. 13 Notably, we did not detect differences in the proliferative capacity of BM endothelial cells after 5-FU administration (not shown).
We next investigated the effects of ectopic expression of ELF4 in the proliferation of HUVECs using a fusion protein. Cells were nucleofected with an ELF4 -green fluorescent protein expression plasmid, purified by cell sorting, and analyzed by DNA content. ELF4 induced the proliferation of HUVECs, as shown by a higher proportion of cells in S phase ( Figure 5A ). Conversely, silencing ELF4 in HUVECs using gene-specific shRNA led to a significant reduction of the number of cells in S phase ( Figure 5B ). To further discriminate between cells in G 0 and cells in G 1 and determine whether quiescence was specifically altered by ELF4, we measured the expression of Ki67 in conjunction with DNA content. As shown for BM cells, quiescent HUVECs were defined as cells with 2n DNA content that were negative for Ki67. Loss of ELF4 resulted in a significant increase in the percentage of cells in G 0 , suggesting that ELF4 promotes cell cycle entry of endothelial cells ( Figure 5C and 5D) . In contrast to ELF4, silencing of ELF1 did not significantly affect the percentage of 2n Ki67
Ϫ cells ( Figure 5C and 5D). The difference in the magnitude of quiescence between primary murine CD45 Ϫ CD31 ϩ and HUVECs is likely due to cellular heterogeneity and the fact that commercial HUVECs are preselected for proliferation. Nevertheless, it is clear in both systems that loss of ELF4 reduces proliferation of endothelial cells and increases the proportion of cells in G 0 . In addition to regulating proliferation of HUVECs, ELF4 modulates tube formation and wound healing (Supplemental Figure II) .
The use of HUVECs allowed us to further investigate the mechanism of cell cycle regulation by immunoblot analysis. As expected from the proliferation assays, loss of ELF4 activity resulted in decreased phosphorylation of Rb ( Figure  6A ). In contrast to normal levels of cyclin D1, cyclin D3, and p21, the expression of CDK4 was diminished by 40% ( Figure  6A) . A rather discrete reduction in CDK4 levels may be due to a combination of transient ELF4 mRNA silencing and the half-life of CDK4 protein. Reduced proliferation of HUVECs treated with ELF4 shRNA could be due to lower expression of CDK4. We performed promoter assays to confirm that ELF4 directly regulates expression of the CDK4 gene. We found that ELF4 activates the CDK4 promoter as efficiently as c-MYC, a known activator of CDK4 ( Figure 6B ). Collectively, our data suggest that ELF4 can promote cell cycle entry of endothelial cells, at least in part by regulating CDK4 expression.
Discussion
Quiescence is a reversible cell cycle arrest that prevents differentiation and ensures longevity of lineage-specific progenitor cells. A better understanding of the regulation of quiescence in endothelial cells is necessary to minimize vascular damage and to accelerate neovascularization of BM in patients undergoing chemo-or radiation therapies. In this study, we demonstrated that the transcription factor ELF4 negatively regulates quiescence in human umbilical cord endothelial cells in vitro and in murine BM endothelial cells in vivo.
The absence of a vascular phenotype in Elf4
Ϫ/Ϫ mice suggests that this transcription factor may have a functional role in vascular remodeling of adult tissues rather than during embryogenesis. Therefore, we tested whether loss of the Elf4 gene leads to alterations in the vascular regeneration postmyelosuppression induced by 5-FU administration. A limitation in our study is the lack of well-defined cell surface markers to identify BM endothelial progenitor cells by flow cytometry. However, the use of human-derived endothelial cells allowed us to study the role of ELF4 in proliferation with greater detail. Interestingly, loss of ELF4 function resulted in increased quiescence of HUVECs, reduced phosphorylation of Rb, and lower expression of cyclindependent kinase 4 (CDK4). There is emerging evidence that CDK4 activity is involved in cellular quiescence. Inhibition of CDK4/6 activity has been shown to increase resistance to radiation in hematopoietic cells. 31 GATA-2 induces HSC quiescence by reducing the levels of CCND3, CDK4, and CDK6. 32 In skin stem cells, NFATc1 targets CDK4 to control stem cell quiescence. 33 In addition to proliferation, transient silencing of ELF4 in HUVECs affected their ability to heal a wound and to form tube-like structures in Matrigel (Supplemental Figure II) . However, ELF4 silencing in HUVECs did not alter cell-cell contacts in a monolayer or vascular endothelial-cadherin levels (not shown). Our findings uncovered a new role of ELF4 in endothelial cells: control of quiescence by activating expression of CDK4.
Our study supports the model that a heightened recovery of SBVs in Elf4 Ϫ/Ϫ mice is associated with the deregulated proliferation of endothelial cells. The failure of endothelial cells to proliferate in the absence of ELF4 can explain the increased resistance to cell cycle-dependent toxicity because endothelial cells in G 0 phase can escape the deleterious effect of 5-FU. Consequently, more "progenitor" endothelial cells can rapidly regenerate SBVs in Elf4 Ϫ/Ϫ mice. Collectively, we propose that ELF4 has dual functions in hematologic recovery post-BM ablation by regulating cell cycle entry in both HSCs 13 and BM endothelial cells. As a consequence, ELF4 activity can contribute to the regeneration of a functional vascular niche. Gene modulation of the ELF4 gene could be used in the future to enhance hematologic recovery of patients undergoing chemotherapy or radiation by accelerating the regeneration of both the hematopoietic system and the vascular niche. The determination of the genes regulated by ELF4 in BM endothelial cells and the mechanism by which ELF4 is regulated remain to be investigated. 
